Tuck, were you surprised how far the stock was taken down today?
As to the acne vulgaris market, the recent Trends in Medicine article (Feb 2018) summarizes the recent American Academy of Dermatology conference on drugs in trials.
"Oral antibiotics – e.g., doxycycline – remain the mainstay of medical treatment of acne,
but there are three new drugs on the horizon that could offer new options – one oral agent
and two topicals. Shari Lipner, MD, PhD, a dermatologist from New York-Presbyterian
Hospital/Weill Cornell Medicine, said none of this is likely to be a home-run for acne
patients, “It’s all about options, and options that make it easier for patients to use, so they
are more compliant and have a better treatment"
She essentially says that there is good data for sarecycline (AGN with PRTK), mixed results with Novan's SB-204, and waiting on DERM's results, now out today.
The stock price of PRTK is not reflecting the good data, it has been trashed. Recent $$ raise did not help.
I am intrigued by DERM due to their asset Lebrikizumab, the anti-IL13 Ab. Some analysts say that this drug may have better dosing than Dupixent, and thus could be a huge asset. Inflammatory skin conditions and anti-IL13 seem to be a very good match. Antibody half life improvement and monthly dosing potential? Do you have a view on L? |
